Literature DB >> 17895038

Clinical implications of poststroke hypothalamo-pituitary adrenal axis dysfunction: A critical literature review.

A J Mitchell.   

Abstract

Persistent hypothalamo-pituitary adrenal axis dysregulation occurs in up to 40% of patients who have suffered a stroke. The degree of hypercortisolemia is partly determined by the size and site of the vascular lesion. Adrenocortical hyperactivity begins almost immediately after a cerebrovasacular infarct but is persistent in an important subgroup of patients. In the early poststroke period (1 day to 1 month) high corticosteroid levels correlate with the presence of an acute confusional state. In the medium term (1 month to 1 year) hypercortisolemia is associated with the development of a major depressive episode and also relates to functional outcome and survival. Neuroanatomical deficits (particularly in the frontal or medial temporal lobes), age of onset, cognitive impairment, and reduced functional status may act as maintaining factors in both the poststroke depression and the adrenocortical hyperactivity. Patients with persisting hypercortisolemia, with or without depression or cognitive impairment, have a worse prognosis with an increased mortality rate. The mechanism for this effect may involve induced hyperglycemia or direct glucocorticoid neurotoxicity, which impairs the brain's capacity for recovery. It is suggested that the cautions use of antiglucocorticoid strategies may be of value in the medical management of the neuropsychiatric complications that follow cerebrovascular accidents.

Entities:  

Year:  1997        PMID: 17895038     DOI: 10.1016/s1052-3057(97)80038-9

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  8 in total

1.  Cerebral energy metabolism during transient hyperglycemia in patients with severe brain trauma.

Authors:  Pedro Diaz-Parejo; Nils Ståhl; Wangbin Xu; Peter Reinstrup; Urban Ungerstedt; Carl-Henrik Nordström
Journal:  Intensive Care Med       Date:  2003-03-25       Impact factor: 17.440

Review 2.  Poststroke Depression Biomarkers: A Narrative Review.

Authors:  Oleg A Levada; Alexandra S Troyan
Journal:  Front Neurol       Date:  2018-07-16       Impact factor: 4.003

3.  Adipose tissue and metabolic and inflammatory responses to stroke are altered in obese mice.

Authors:  Michael J Haley; Graham Mullard; Katherine A Hollywood; Garth J Cooper; Warwick B Dunn; Catherine B Lawrence
Journal:  Dis Model Mech       Date:  2017-08-10       Impact factor: 5.758

4.  Hyperglycemia in bacterial meningitis: a prospective cohort study.

Authors:  Ewout S Schut; Willeke F Westendorp; Jan de Gans; Nyika D Kruyt; Lodewijk Spanjaard; Johannes B Reitsma; Diederik van de Beek
Journal:  BMC Infect Dis       Date:  2009-05-08       Impact factor: 3.090

Review 5.  Cortisol levels and the severity and outcomes of acute stroke: a systematic review.

Authors:  Amanda Jayne Barugh; Paul Gray; Susan Deborah Shenkin; Alasdair Maurice Joseph MacLullich; Gillian Elizabeth Mead
Journal:  J Neurol       Date:  2014-01-30       Impact factor: 4.849

6.  Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS).

Authors:  Michael Knops; Claudia G Werner; Nadja Scherbakov; Jochen Fiebach; Jens P Dreier; Andreas Meisel; Peter U Heuschmann; Gerd J Jungehülsing; Stephan von Haehling; Ulrich Dirnagl; Stefan D Anker; Wolfram Doehner
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-03-13       Impact factor: 12.910

Review 7.  The neurobiological pathogenesis of poststroke depression.

Authors:  Chao Feng; Min Fang; Xue-Yuan Liu
Journal:  ScientificWorldJournal       Date:  2014-03-04

8.  Risk factors associated with poor outcomes in patients with brain abscesses.

Authors:  Seok-Jin Ko; Kyung-Jae Park; Dong-Hyuk Park; Shin-Hyuk Kang; Jung-Yul Park; Yong-Gu Chung
Journal:  J Korean Neurosurg Soc       Date:  2014-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.